In the News: UVA Highlights First-in-Human Trial of hCitH3-mAb for Sepsis-Induced ARDS
As recently reported by the University of Virginia (link), a first-in-human clinical trial has begun evaluating hCitH3-mAb, a novel monoclonal antibody therapy targeting sepsis-induced acute respiratory distress syndrome (ARDS). Sepsis and ARDS remain leading causes of mortality in intensive care units, with limited treatment options beyond supportive care. The investigational antibody was developed to neutralize…